Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | NPC1 | O15118 | 5/20 | 0.66 |
| ▸ | RAB9A | P51151 | 5/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | MAPK10 | P53779 | 6/20 | 0.62 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.59 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | MGAM | O43451 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29953857 | 1.00 | KDM4E (0.66) | KDM4EKMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL28023165 | 0.84 | KDM4E (0.64) | KDM4EKMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL28465286 | 0.80 | KMT2A (1.00) | KDM4EKMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL1898286 | 0.77 | NPC1 (0.63) | KDM4EKMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL1898285 | 0.77 | NPC1 (0.63) | KDM4EKMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL6936350 | 0.75 | RAB9A (0.78) | KDM4EKMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL7105109 | 0.75 | RAB9A (0.78) | KDM4EKMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL376644 | 0.75 | ALDH1A1 (0.59) | KDM4EKMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL29641181 | 0.75 | ALDH1A1 (0.59) | KDM4EKMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL11365151 | 0.74 | PLAUR (0.53) | KDM4EKMT2ANPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2723737-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | Kyorin Pharmaceutical Co., Ltd. (JP) | 2014-04-30 | — | — | EP | disclosed |
| WO-2013003383-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2013-01-03 | — | — | WO | disclosed |
| US-7538109-B2 | Quinoxalin-3-one derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2009-05-26 | — | — | US | disclosed |
| US-7538109-B2 | Quinoxalin-3-one derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2009-05-26 | — | — | US | disclosed |
| US-7538109-B2 | Quinoxalin-3-one derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2009-05-26 | — | — | US | disclosed |
| EP-1620409-B1 | QUINOXALIN-3-ONE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-01-09 | — | — | EP | disclosed |
| EP-1620409-B1 | QUINOXALIN-3-ONE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-20070027157-A1 | Quinoxalinone-3-one derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-01 | — | — | US | disclosed |
| US-20070027157-A1 | Quinoxalinone-3-one derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-01 | — | — | US | disclosed |
| US-20070027157-A1 | Quinoxalinone-3-one derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-01 | — | — | US | disclosed |
| CN-1780820-A | Quinoxalinone-3- one derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2006-05-31 | — | — | CN | disclosed |
| EP-1620409-A1 | QUINOXALIN-3-ONE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004096780-A1 | QUINOXALINONE-3- ONE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096780-A1 | QUINOXALINONE-3- ONE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027157-A1 | Quinoxalinone-3-one derivatives as orexin receptor antagonists | HCRTR1, HCRTR2, NPY1R | KDM4E 1645/4885KMT2A 2120/4885NPC1 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.